Eisai and Biogen are now working on the next steps after the TGA confirmed its non-approval of lecanemab for the treatment of mild cognitive impairment due to Alzheimer’s disease and early Alzheimer’s disease. …
Eisai and Biogen working on next steps after TGA confirms non-approval of Alzheimer’s therapy
March 4, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Eisai and Biogen working on next steps after TGA confirms non-approval of Alzheimer’s therapy
March 4, 2025 - - Latest News -
CSL Seqirus secures Australia-NZ rights to commercialise cholesterol-lowering therapy
March 4, 2025 - - Latest News -
Is personalised gene therapy ready for prime time?
March 4, 2025 - - Latest News -
Astellas welcomes TGA approval of cancer combination as first-line treatment
March 4, 2025 - - Latest News -
Sandoz backs Australian medicinal cannabis company in ten-year agreement
March 3, 2025 - - BioPharma -
Australian startup launches the world's first commercial biological computer
March 3, 2025 - - Australian Biotech -
TGA approves first biological therapy for serious respiratory condition
March 3, 2025 - - Latest News